US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
A potential label for the US consumer health product industry’s January-March period might be the dismissal of a challenge to an iconic analgesic’s label and the easing of a regulatory burden for filing OTC label updates combined with the introduction of a first-ever nonprescription label.
US OTC drug and dietary supplement firms’ reports of their results for the first three months of 2024 begins on...
Adopting an online approach, BioGaia is set to enter the Dutch market for probiotic dietary supplements. The firm announced the move as it reported lower sales in Q1.
An increasing awareness of and interest in gut health helped the global OTC market grow by 4.6% in value terms in 2024, according to IQVIA Consumer Health.
Dermapharm shakes up management of Arkopharma subsidiary in Spain with turnaround plan not showing results.
C&D reports Q1 net sales dropped 2.4% to $1.48bn, below its guidance for around 1% growth. Its brands’ sales at retail and market share grew in the quarter, but “experienced slowing category growth in the US market” as retailers reduced inventory levels.
UK-based firm will use the capital to launch its AxisBiotix skin health supplements in Superdrug stores and to develop new product formats.
Czech Republic's Zentiva snaps up Aboca portfolio adding supplement brands marketed in European countries such France, Italy and Spain.
In remarks at recent investor conference reflecting comments from across the US consumer health sector, Kenvue chief Thibaut Mongon says, “I'm going to state the obvious. The environment is very fluid.”
